Targeting the Renin-Angiotensin System (RAS) for Neuropsychiatric Disorders

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2022 Sep 29

PMID 36173067

Authors

Aline Silva de Miranda

Danielle S Macedo

Natalia P Rocha

Antonio L Teixeira

Affiliations

Soon will be listed here.

Abstract

Background: Neuropsychiatric disorders, such as mood disorders, schizophrenia, and Alzheimer's disease (AD) and related dementias, are associated to significant morbidity and mortality worldwide. The pathophysiological mechanisms of neuropsychiatric disorders remain to be fully elucidated, which has hampered the development of effective therapies. The Renin Angiotensin System (RAS) is classically viewed as a key regulator of cardiovascular and renal homeostasis. The discovery that RAS components are expressed in the brain pointed out a potential role for this system in central nervous system (CNS) pathologies. The understanding of RAS involvement in the pathogenesis of neuropsychiatric disorders may contribute to identifying novel therapeutic targets.

Aims: We aim to report current experimental and clinical evidence on the role of RAS in physiology and pathophysiology of mood disorders, schizophrenia, AD and related dementias. We also aim to discuss bottlenecks and future perspectives that can foster the development of new related therapeutic strategies.

Conclusion: The available evidence supports positive therapeutic effects for neuropsychiatric disorders with the inhibition/antagonism of the ACE/Ang II/AT1 receptor axis or the activation of the ACE2/Ang-(1-7)/Mas receptor axis. Most of this evidence comes from pre-clinical studies and clinical studies lag much behind, hampering a potential translation into clinical practice.

Citing Articles

Potentiation of NMDA Receptors by AT1 Angiotensin Receptor Activation in Layer V Pyramidal Neurons of the Rat Prefrontal Cortex.

Hanuska A, Ribiczey P, Kato E, Papp Z, Varga Z, Giricz Z Int J Mol Sci. 2024; 25(23).

PMID: 39684355 PMC: 11641273. DOI: 10.3390/ijms252312644.

LncRNA CCAT2 Knockdown Alleviates Pressure Overload or Ang II-Induced Cardiac Hypertrophy Via Disruption of the Wnt/β-Catenin Signaling.

Zhang X, Chen Z, Zhang N, Yu B, Li W, Zhang M Arq Bras Cardiol. 2024; 121(10):e20240181.

PMID: 39536197 PMC: 11634213. DOI: 10.36660/abc.20240181.

Pathophysiological Mechanisms of Psychosis-Induced Atrial Fibrillation: The Links between Mental Disorder and Arrhythmia.

Chen P, Kao Y, Chen Y Rev Cardiovasc Med. 2024; 25(9):343.

PMID: 39355592 PMC: 11440412. DOI: 10.31083/j.rcm2509343.

New insights into the role of Klotho in inflammation and fibrosis: molecular and cellular mechanisms.

Zhao X, Han D, Zhao C, Yang F, Wang Z, Gao Y Front Immunol. 2024; 15:1454142.

PMID: 39308872 PMC: 11412887. DOI: 10.3389/fimmu.2024.1454142.

Comparison of brain gray matter volume changes in peritoneal dialysis and hemodialysis patients with chronic kidney disease: a VBM study.

Xiao F, Zhou L, Li Y, Zhang C, Liu Y, Yu H Front Neurosci. 2024; 18:1394169.

PMID: 38737098 PMC: 11082365. DOI: 10.3389/fnins.2024.1394169.

References

Hammer A, Stegbauer J, Linker R . Macrophages in neuroinflammation: role of the renin-angiotensin-system. Pflugers Arch. 2017; 469(3-4):431-444. DOI: 10.1007/s00424-017-1942-x. View

Campagnole-Santos M, Heringer S, Batista E, Khosla M, Santos R . Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol. 1992; 263(1 Pt 2):R89-94. DOI: 10.1152/ajpregu.1992.263.1.R89. View

Germain L, Chouinard G . Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry. 1989; 25(4):489-93. DOI: 10.1016/0006-3223(89)90203-5. View

Ayyub M, Najmi A, Akhtar M . Protective Effect of Irbesartan an Angiotensin (AT1) Receptor Antagonist in Unpredictable Chronic Mild Stress Induced Depression in Mice. Drug Res (Stuttg). 2016; 67(1):59-64. DOI: 10.1055/s-0042-118172. View

Villapol S, Balarezo M, Affram K, Saavedra J, Symes A . Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain. 2015; 138(Pt 11):3299-315. PMC: 4731413. DOI: 10.1093/brain/awv172. View

Leong D, Terron J, Falcon-Neri A, Armando I, Ito T, Johren O . Restraint stress modulates brain, pituitary and adrenal expression of angiotensin II AT(1A), AT(1B) and AT(2) receptors. Neuroendocrinology. 2002; 75(4):227-40. DOI: 10.1159/000054714. View

Li N, Lee A, Whitmer R, Kivipelto M, Lawler E, Kazis L . Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010; 340:b5465. PMC: 2806632. DOI: 10.1136/bmj.b5465. View

Dos Santos Picanco L, Ozela P, Brito M, Pinheiro A, Padilha E, Braga F . Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Curr Med Chem. 2018; 25(26):3141-3159. DOI: 10.2174/0929867323666161213101126. View

Simoes E Silva A, Teixeira M . ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res. 2016; 107:154-162. DOI: 10.1016/j.phrs.2016.03.018. View

10.

Royea J, Lacalle-Aurioles M, Trigiani L, Fermigier A, Hamel E . AT2R's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease. Hypertension. 2020; 75(6):1464-1474. DOI: 10.1161/HYPERTENSIONAHA.119.14431. View

11.

Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H . Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?. Eur Arch Psychiatry Clin Neurosci. 2000; 249 Suppl 3:14-22. DOI: 10.1007/pl00014168. View

12.

Lazaroni T, Bastos C, Moraes M, Santos R, Pereira G . Angiotensin-(1-7)/Mas axis modulates fear memory and extinction in mice. Neurobiol Learn Mem. 2015; 127:27-33. DOI: 10.1016/j.nlm.2015.11.012. View

13.

Block C, Santos R, Brosnihan K, Ferrario C . Immunocytochemical localization of angiotensin-(1-7) in the rat forebrain. Peptides. 1988; 9(6):1395-401. DOI: 10.1016/0196-9781(88)90208-2. View

14.

Lavoie J, Sigmund C . Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003; 144(6):2179-83. DOI: 10.1210/en.2003-0150. View

15.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

16.

Guo D, Sun Y, Hamet P, Inagami T . The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res. 2001; 11(3):165-80. DOI: 10.1038/sj.cr.7290083. View

17.

Walker L, McAleese K, Thomas A, Johnson M, Martin-Ruiz C, Parker C . Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015; 129(5):729-48. DOI: 10.1007/s00401-015-1406-3. View

18.

Saavedra J, Sanchez-Lemus E, Benicky J . Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology. 2010; 36(1):1-18. PMC: 2998923. DOI: 10.1016/j.psyneuen.2010.10.001. View

19.

Gong X, Hu H, Qiao Y, Xu P, Yang M, Dang R . The Involvement of Renin-Angiotensin System in Lipopolysaccharide-Induced Behavioral Changes, Neuroinflammation, and Disturbed Insulin Signaling. Front Pharmacol. 2019; 10:318. PMC: 6454872. DOI: 10.3389/fphar.2019.00318. View

20.

Schiavone M, Santos R, Brosnihan K, Khosla M, Ferrario C . Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 1988; 85(11):4095-8. PMC: 280369. DOI: 10.1073/pnas.85.11.4095. View